Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT03954756
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT03950271
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03947242
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT03942068
Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03939962
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03881761
- Locations
- 🇨🇳
Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03881774
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT03790228
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03755115
- Locations
- 🇨🇳
Tian Tongde, Zhengzhou, Henan, China
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT03735966
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath